Unravelling the mechanisms of clozapine-induced neutropenia in treatment-resistant schizophrenia using cellular genomics

Background: About one-third of individuals with schizophrenia do not respond to first-line antipsychotics. Clozapine has superior efficacy for treatment-resistant schizophrenia (TRS), yet remains underutilised partly due to a 1% risk of potentially fatal clozapine-induced neutropenia (CIN). However, the biological mechanisms underlying CIN remain poorly understood. Methods: We recruited six individuals with TRS who had previously received clozapine: three who ceased clozapine following CIN and three who stopped for reasons unrelated to CIN. Peripheral blood mononuclear cells were collected and

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.